Shivani Nyati, Head of Wealth at Swastika Investmart, assigned an 'avoid' rating to the public issue, stating, "The company's financial performance has been underwhelming. It faced significant challenges in FY 2022-23, although there are some indications of recovery in FY24. However, the valuations of the public issue don't offer much potential for investors."
Suraksha Diagnostic IPO GMP Live Updates: Suraksha Diagnostic issue fully subscribed on Day 3 - The Economic TimesSuraksha Diagnostic IPO subscribed 1.27 times on final day of bidding. Check GMP, Price Band, Key Dates and Review - The Economic TimesSuraksha Diagnostics IPO day 3: GMP, subscription status to review. Apply or not? - MintSuraksha Diagnostic’s IPO will close today, till now only 35% subscribed, GMP flat, what bet should be placed? - Morning ExpressSuraksha Diagnostics IPO day 3: GMP, subscription status to review. Apply or not? - Qrius
